texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Tyler

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphoma

Location: Texas Oncology-Canton

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Melanoma

Indication: Melanoma

Location: Texas Oncology-Paris

Phase:

Title: A US MULTI-SITE OBSERVATIONAL STUDY IN PATIENTS WITH UNRESECTABLE AND METASTATIC MELANOMA: THE OPTIMIZE STUDY View

Non-Melanoma Skin Cancer

Indication: Non-Melanoma Skin Cancer

Location: Texas Oncology-Paris

Phase:

Title: Use of Radiation in Non-Melanoma Skin Cancer: Retrospective Study at a Rural Cancer Center View

Other

Indication: Other

Location: Texas Oncology-Tyler

Phase:

Title: The Expression Project for Oncology (expO) View

Indication: Other

Location: Texas Oncology-Canton

Phase:

Title: The Expression Project for Oncology (expO) View

Renal Cancer

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Sarcoma

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Skin Cancer

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Testicular Cancer

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thymomas

Indication: Thymomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Thyroid Cancer

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Uterine Cancer

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Vaginal Cancer

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Canton

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Lymphoma

Location: Texas Oncology-Canton

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Other

Location: Texas Oncology-Canton

Phase:

Title: The Expression Project for Oncology (expO) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Longview Cancer Center

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Texas Oncology-Paris

Indication: Melanoma

Location: Texas Oncology-Paris

Phase:

Title: A US MULTI-SITE OBSERVATIONAL STUDY IN PATIENTS WITH UNRESECTABLE AND METASTATIC MELANOMA: THE OPTIMIZE STUDY View

Indication: Non-Melanoma Skin Cancer

Location: Texas Oncology-Paris

Phase:

Title: Use of Radiation in Non-Melanoma Skin Cancer: Retrospective Study at a Rural Cancer Center View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Tyler

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Lymphoma

Location: Texas Oncology-Tyler

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Other

Location: Texas Oncology-Tyler

Phase:

Title: The Expression Project for Oncology (expO) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

No Phase

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Melanoma

Location: Texas Oncology-Paris

Phase:

Title: A US MULTI-SITE OBSERVATIONAL STUDY IN PATIENTS WITH UNRESECTABLE AND METASTATIC MELANOMA: THE OPTIMIZE STUDY View

Indication: Non-Melanoma Skin Cancer

Location: Texas Oncology-Paris

Phase:

Title: Use of Radiation in Non-Melanoma Skin Cancer: Retrospective Study at a Rural Cancer Center View

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Lymphoma

Location: Texas Oncology-Tyler

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Other

Location: Texas Oncology-Tyler

Phase:

Title: The Expression Project for Oncology (expO) View

Indication: Lung Cancer

Location: Texas Oncology-Canton

Phase:

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase:

Title: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements View

Indication: Lymphoma

Location: Texas Oncology-Canton

Phase:

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Other

Location: Texas Oncology-Canton

Phase:

Title: The Expression Project for Oncology (expO) View

Phase I

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Sarcoma

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Indication: Sarcoma

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients with Advanced Solid Tumors (BBI401-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (BBI-DSP7888-101) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indicati View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I

Title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (516-001) View

Phase I/II

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: Genentech PMT4979g: AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN''S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PAT View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: I/II

Title: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201 View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: I/II

Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111) View

Phase II

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Skin Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thymomas

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Canton

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Uterine Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Indication: Vaginal Cancer

Location: Texas Oncology-Canton

Phase: II

Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627) View

Phase III

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000- View

Indication: Renal Cancer

Location: Texas Oncology-Canton

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Canton

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase IV

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Canton

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View